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“The deliberate sin of the ﬁ  rst man is the 
cause of original sin”
—[Saint] Augustine of Hippo, Algerian Christian theologian 
(354 AD–430 AD), De nuptiis et concupiscientia [On Marriage 
and Concupiscence], II, xxvi, 43
W
hat epidemiologist Thomas Francis, Jr. (1900–1969) 
was thinking when pondering certain inexplicable 
serologic data from a 1946 inﬂ  uenza vaccine trial may nev-
er be known. Whether in religious reverence for the beauty 
of science or impish delight fueled by the martini breaks 
of which he was so fond, Francis coined the term “original 
antigenic sin” to describe a curious new immunologic phe-
nomenon. Elsewhere in this issue, Adalja and Henderson 
propose that original antigenic sin has altered the popula-
tion age–speciﬁ  c incidence of infection and disease caused 
by inﬂ  uenza A pandemic (H1N1) 2009 virus and that public 
health responses must account for the disruption (1). What 
is original antigenic sin, what is its immunologic basis, and 
into what sort of trouble is it getting us?
Discovery of inﬂ  uenza viruses in the early 1930s ig-
nited a search to understand the epidemiology of pandemic/
endemic inﬂ  uenza. Serologic data showed that decendents 
of the 1918 pandemic inﬂ  uenza virus were still circulating 
and were changing antigenically (we would now say drift-
ing and undergoing intrasubtypic reassortment); that con-
temporary human and swine viruses were closely related; 
and that over a lifetime of repeated exposures, different hu-
man birth cohorts were acquiring fundamentally different 
inﬂ  uenza infection experiences. The surprise appearance 
in 1946 of a new and antigenically different inﬂ  uenza A 
virus (designated inﬂ  uenza A′ and recently shown to be a 
subtype H1N1 intrasubtypic reassortant) provided Francis 
a unique opportunity. College students participating in a 
1946 trial of the old 1946 virus vaccine were infected in 
March 1947 with the new A′ virus. Surprisingly, these stu-
dents developed low serologic titers to the new infecting 
virus and higher seroconverting titers to old viruses with 
which they previously had been infected. Moreover, recent 
recipients of the old virus vaccine had the highest serocon-
verting titers of all to the old—but not to the new—virus 
(2,3).
Absorption studies, in which various viruses were used 
to selectively remove serum antibodies, suggested that re-
peat exposures to dominant antigens of ﬁ  rst-infecting vi-
ruses, when seen later as lesser or secondary antigens on 
subsequently infecting viruses, somehow reinforced anti-
body responses to the original strains at the apparent ex-
pense of responses to newer strains (4). Francis announced 
“the doctrine of original antigenic sin” (5,6): “[t]he anti-
body-forming mechanisms appear to be oriented by the 
initial infections of childhood so that exposures later in 
life to antigenically related strains result in a progressive 
reinforcement of the primary antibody” (3). Later studies 
by many investigators showed original antigenic sin to be 
a general phenomenon associated with numerous related/
sequentially infecting virus strains that contain multiple 
external epitopes of varying cross-speciﬁ  city (i.e., ability 
to elicit cross-reactive antibody), including antigenically 
drifting viruses such as inﬂ  uenza A, and the more stable 
ﬂ  aviviruses, which circulate concurrently as multiple dis-
tinct viruses, virus serotypes, and virus strains (7,8).
Original antigenic sin seems to be most pronounced 
when sequential viruses are of intermediate antigenic relat-
edness; when they are antigenically complex; and when se-
quential exposure intervals are long, consistent with ongo-
ing selection and expansion of lymphocyte clones that have 
increasing antibody avidity at key cross-reactive epitopes 
(7–10) and possibly with epitope competition between naïve 
and antigen-speciﬁ  c B cells (8). A phenomenon analogous 
to original antigenic sin also has been described with cyto-
toxic T lymphocytes (11). Although conclusive evidence in 
humans is lacking, original antigenic sin recently has come 
under scrutiny as a possible cause of viral immune escape, 
enhanced disease severity, decreased efﬁ  cacy of inﬂ  uenza 
vaccines (8,12–14), and increased incidence of inﬂ  uenza in 
2009 after vaccination with a related virus in 2008–2009 
(15). On a positive note, original antigenic sin has also been 
linked to vaccine-induction of heterosubtypic neutralizing 
antibodies (16).
Adalja and Henderson note that the apparently lower 
incidence and severity of disease in older persons during 
the 2009–10 inﬂ  uenza pandemic probably reﬂ  ects immuni-
ty to previously circulating inﬂ  uenza (H1N1) subtypes (1). 
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antigenic sin but emphasize the importance of exposures 
to the changing hemagglutinin glycosylation patterns of 
earlier inﬂ  uenza (H1N1) subtypes (e.g., those circulating 
before and after 1948) on a background of relatively con-
served T-cell epitopes (14). However, the possibility that 
the age structure of pandemic (H1N1) 2009 infection is due 
simply to single or repeated exposures to different or differ-
entially exposed hemagglutinin epitopes has not been ruled 
out. Useful information bearing on these questions might 
be gained by comparing antibody levels, antibody reactivi-
ties, and the original antigenic sin phenomenon in serum 
samples from the various age cohorts that had early expo-
sures to markedly different (or to no) inﬂ  uenza (H1N1) se-
rotypes, e.g., persons born before 1918; during 1918–1927, 
1928–1946, 1947–1956, and 1957–1976; and after 1976. 
Of related interest are the 2009 inﬂ  uenza experiences of the 
≈25.6 million persons living in America vaccinated with 
the 1976 Hsw1N1 vaccine (17), including 2.5 million born 
during 1957–1975, when inﬂ  uenza (H1N1) viruses did not 
circulate
The current pandemic provides the challenge to pub-
lic health responses that Adjala and Henderson describe, 
as well as an opportunity to extend the efforts of Francis to 
better understand the complicated epidemiology of inﬂ  u-
enza. Is original antigenic sin really a sin from which our 
immune systems need to be saved? Or is it an epidemio-
logic blessing in disguise? We have much more to learn. As 
St. Augustine wrote (Confessiones, 8, 7): “Lord make me 
chaste—but not yet.”
Dr Morens is an epidemiologist and historian who serves as 
senior advisor to the director, National Institute of Allergy and In-
fectious Diseases. His interests include infectious disease patho-
genesis, determinants of disease emergence, and the history of 
infectious diseases.
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